RU2002127778A - IMPROVED METHOD FOR TREATING NEOVASCULARIZATION - Google Patents

IMPROVED METHOD FOR TREATING NEOVASCULARIZATION

Info

Publication number
RU2002127778A
RU2002127778A RU2002127778/15A RU2002127778A RU2002127778A RU 2002127778 A RU2002127778 A RU 2002127778A RU 2002127778/15 A RU2002127778/15 A RU 2002127778/15A RU 2002127778 A RU2002127778 A RU 2002127778A RU 2002127778 A RU2002127778 A RU 2002127778A
Authority
RU
Russia
Prior art keywords
photosensitive agent
use according
inhibitors
patient
drug
Prior art date
Application number
RU2002127778/15A
Other languages
Russian (ru)
Other versions
RU2271222C2 (en
Inventor
Ромулус Кимбро БРАЗЗЕЛЛ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2002127778A publication Critical patent/RU2002127778A/en
Application granted granted Critical
Publication of RU2271222C2 publication Critical patent/RU2271222C2/en

Links

Claims (10)

1. Применение антиангиогенного агента в сочетании с фоточувствительным агентом для получения лекарственного средства, предназначенного для улучшенного лечения, направленного на устранение у пациента нежелательной новой сосудистой сети, обусловленной ХНВ.1. The use of an antiangiogenic agent in combination with a photosensitive agent for the manufacture of a medicament intended for improved treatment aimed at eliminating an unwanted new vasculature due to CVD in a patient. 2. Применение по п.1, где способ более эффективного фотодинамического лечения предусматривает (а) введение пациенту эффективного количества антиангиогенного лекарственного средства, (б) введение пациенту эффективного количества фоточувствительного агента, и (в) облучение нежелательной новой сосудистой сети светом с длиной волны, при которой происходит его абсорбция фоточувствительным агентом.2. The use according to claim 1, where the method of more effective photodynamic treatment involves (a) administering to the patient an effective amount of an antiangiogenic drug, (b) administering to the patient an effective amount of a photosensitive agent, and (c) irradiating the unwanted new vasculature with light with a wavelength, in which it is absorbed by a photosensitive agent. 3. Применение по пп.1 и 2, где антиангиогенное лекарственное средство вводят за 1-4 недели до введения фоточувствительного агента.3. The use according to claims 1 and 2, where the antiangiogenic drug is administered 1-4 weeks before the administration of the photosensitive agent. 4. Применение по пп.1 и 2, где введение антиангиогенного лекарственного средства и фоточувствительного агента осуществляют одновременно.4. The use according to claims 1 and 2, where the administration of the antiangiogenic drug and the photosensitive agent is carried out simultaneously. 5. Применение по пп.1 и 2, где антиангиогенное лекарственное средство вводят через 1-4 недели после введения фоточувствительного агента.5. The use according to claims 1 and 2, where the antiangiogenic drug is administered 1-4 weeks after administration of the photosensitive agent. 6. Применение по п.1, где антиангиогенное лекарственное средство выбирают из группы, включающей инигибиторы протеинкиназы С (ПКС), ингибиторы гормона роста и IGF-1, ингибиторы сосудистого эндотелиального фактора роста, ингибиторы циклооксигеназы II, ингибиторы ангиотензина II, ингибиторы NF-k В и антагонисты PLA2.6. The use according to claim 1, where the anti-angiogenic drug is selected from the group consisting of protein kinase C inhibitors (PKC), growth hormone inhibitors and IGF-1, vascular endothelial growth factor inhibitors, cyclooxygenase II inhibitors, angiotensin II inhibitors, NF-k inhibitors B and antagonists of PLA2. 7. Применение по п.6, где антиангиогенное лекарственное средство выбирают из группы, включающей ПКС и VEGF, прежде всего из группы ингибиторов ПКС.7. The use according to claim 6, where the anti-angiogenic drug is selected from the group comprising PKC and VEGF, especially from the group of PKC inhibitors. 8. Применение по п.7, где антиангиогенное лекарственное средство выбирают из группы, включающей N-бензоилстауроспорин, CGP 79787 и октреотид, и наиболее предпочтительно оно представляет собой N-бензоилстауроспорин.8. The use according to claim 7, where the antiangiogenic drug is selected from the group consisting of N-benzoylstaurosporine, CGP 79787 and octreotide, and most preferably it is N-benzoylstaurosporine. 9. Применение по п.1, где фоточувствительный агент выбирают из группы, включающей порфирин и пурпурин, и наиболее предпочтительно он представляет собой порфирин.9. The use according to claim 1, where the photosensitive agent is selected from the group comprising porphyrin and purpurin, and most preferably it is porphyrin. 10. Способ улучшенного лечения у пациента нежелательной новой сосудистой сети, предусматривающий следующие стадии: (а) введение пациенту эффективного количества антиангиогенного лекарственного средства, (б) введение пациенту эффективного количества фоточувствительного агента, и (в) облучение нежелательной новой сосудистой сети светом с длиной волны, при которой происходит его абсорбция фоточувствительным агентом.10. A method for improved treatment of an unwanted new vasculature in a patient, comprising the steps of: (a) administering to the patient an effective amount of an antiangiogenic drug, (b) administering to the patient an effective amount of a photosensitive agent, and (c) irradiating the unwanted new vasculature with light with a wavelength at which it is absorbed by a photosensitive agent.
RU2002127778/15A 2000-03-24 2001-03-22 Improved method for treatment of neovascularization RU2271222C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19180700P 2000-03-24 2000-03-24
US60/191,807 2000-03-24

Publications (2)

Publication Number Publication Date
RU2002127778A true RU2002127778A (en) 2004-04-10
RU2271222C2 RU2271222C2 (en) 2006-03-10

Family

ID=22707008

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002127778/15A RU2271222C2 (en) 2000-03-24 2001-03-22 Improved method for treatment of neovascularization

Country Status (21)

Country Link
US (4) US20010039438A1 (en)
EP (1) EP1265636A2 (en)
JP (1) JP2003528926A (en)
KR (2) KR20020082487A (en)
CN (1) CN100398153C (en)
AR (1) AR032151A1 (en)
AU (2) AU5040101A (en)
BR (1) BR0109499A (en)
CA (1) CA2403612A1 (en)
CZ (1) CZ20023174A3 (en)
EE (1) EE200200547A (en)
HU (1) HUP0300347A3 (en)
IL (1) IL151833A0 (en)
MX (1) MXPA02009351A (en)
NO (1) NO20024486D0 (en)
NZ (1) NZ521360A (en)
PL (1) PL359027A1 (en)
RU (1) RU2271222C2 (en)
UA (1) UA75350C2 (en)
WO (1) WO2001074389A2 (en)
ZA (1) ZA200207638B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ521360A (en) * 2000-03-24 2004-07-30 Novartis Ag Improved treatment of neovascularization
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
GEP20063755B (en) * 2001-11-09 2006-02-27 Eyetech Pharmaceuticals Use of VEGF Inhibiting Agents for Treating Ocular Neovascular Diseases
JP2006501902A (en) * 2002-10-03 2006-01-19 ライト サイエンシズ コーポレイション System and method for exciting photosensitive compounds in ocular tissue
EP1651161B1 (en) 2003-08-07 2011-10-19 HealOr Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US20050043786A1 (en) * 2003-08-18 2005-02-24 Medtronic Ave, Inc. Methods and apparatus for treatment of aneurysmal tissue
FR2867189A1 (en) * 2004-03-08 2005-09-09 Ludovic Bourre New compound comprising protein kinase regulator and photoactivatable molecule, useful for treating protein kinase-related diseases, e.g. tumors and inflammation
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
WO2006015016A2 (en) 2004-07-30 2006-02-09 Massachusetts Eye And Ear Infirmary Photodynamic therapy and compositions for treating ocular glaucoma
ZA200802546B (en) 2005-08-29 2009-10-28 Healor Ltd Methods and compositions for prvention and treatment of diabetic and aged skin
US8753673B2 (en) * 2006-05-23 2014-06-17 Taiwan Liposome Co. Ltd. Liposome composition for delivery of a therapeutic agent to eyes
CN102755649A (en) * 2007-07-30 2012-10-31 希尔洛有限公司 Pharmaceutical composition and related methods
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
ES2468827T3 (en) 2010-01-14 2014-06-17 Sanwa Kagaku Kenkyusho Co., Ltd Pharmaceutical product to prevent or treat disorders accompanied by ocular angiogenesis and / or elevated ocular vascular permeability
RU2449821C1 (en) * 2010-09-01 2012-05-10 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "МНИОИ им. П.А.Герцена Минздравсоцразвития России") Method for modifying photodynamic therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
CA2087902C (en) * 1992-02-05 2006-10-17 Narendra Raghunathji Desai Liposome compositions of porphyrin photosensitizers
DE947222T1 (en) * 1992-11-20 2000-05-04 Univ British Columbia Process for activating photosensitive agents
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5707608A (en) * 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
US6214819B1 (en) * 1998-11-23 2001-04-10 Novartis Ag Method for treating ocular neovascular diseases
PL349216A1 (en) * 1998-12-23 2002-07-01 Searle & Co Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia
US6271233B1 (en) * 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
AU2001227837A1 (en) * 2000-01-12 2001-07-24 Light Sciences Corporation Novel treatment for eye disease
CA2714081C (en) * 2000-02-10 2013-08-06 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
NZ521360A (en) * 2000-03-24 2004-07-30 Novartis Ag Improved treatment of neovascularization

Similar Documents

Publication Publication Date Title
RU2002127778A (en) IMPROVED METHOD FOR TREATING NEOVASCULARIZATION
RU2271222C2 (en) Improved method for treatment of neovascularization
TW448045B (en) Improved vision through photodynamic therapy of the eye
Dolmans et al. Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy
JP3598306B2 (en) Bioactivation of photosensitizers in blood through skin
ES2322030T3 (en) PROCEDURES AND COMPOSITIONS OF TREATMENT OF NEOVASCULARIZATION AND EYE NERVOUS INJURIES.
JP2003528926A5 (en)
AU2001250401A1 (en) Improved treatment of neovascularization
ATE491715T1 (en) OLIGORIBONUCLEOTIDES AND METHOD FOR USE THEREOF IN THE TREATMENT OF FIBROTIC DISEASES AND OTHER DISEASES
CA2296997A1 (en) Treatment of congestive heart failure
AU2002230567A1 (en) Compositions for treatment of ocular neovascularization and neural injury
JP2007505939A (en) Combinations of VEGF receptor inhibitors with other therapeutic agents
EP1570859A2 (en) Improved treatment of neovascularization
RU2211714C2 (en) Method for treating malignant neoplasms
SU1748836A1 (en) Method for treating the cases of acute and chronic rejection of liver allograft
AR122388A1 (en) METHODS TO TREAT CANCER
RU2002101349A (en) METHOD FOR TREATING CHRONIC PROSTATITIS
RU2004104573A (en) METHOD OF IMMUNO CORRECTION IN CARDIOSURGICAL PATIENTS WITH INFECTIOUS ENDOCARDITIS